Analyst Tara Bancroft of TD Cowen maintained a Buy rating on Vaxcyte, retaining the price target of $50.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Tara Bancroft’s rating is based on promising data from Vaxcyte’s vaccine trials, which suggest strong potential for their products. The recent Phase II data for VAX-24 in infants showed that non-inferiority criteria for immunogenicity were met for most serotypes, indicating robust immune responses. The dose-dependent increase in immunogenicity without evidence of increased carrier suppression further supports the efficacy of the vaccine, particularly with the optimized dosing strategy being tested in the VAX-31 infant study.
Additionally, the potential for improved titers when VAX-24 is co-administered with a flu vaccine provides an added advantage over existing vaccines like Prevnar. The expectation of positive Phase III data in 2026 and the current undervaluation of Vaxcyte’s stock contribute to the Buy rating. These factors combined suggest a strong outlook for Vaxcyte, making it an attractive investment opportunity.